http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Cheng-Chen Chang,Ming-Hong Hsieh,Jong-Yi Wang,Nan-Ying Chiu,Yu-Hsun Wang,Jeng-Yuan Chiou,Hsiang-Hsiung Huang,Po-Chung Ju 대한신경정신의학회 2018 PSYCHIATRY INVESTIGATION Vol.15 No.11
Objective Several cell line studies have demonstrated thioridazine’s anticancer, multidrug resistance-reversing and apoptosis-inducing properties in various tumors. We conducted this nationwide population-based study to investigate the association between thioridazine use and cancer risk among adult patients with schizophrenia. Methods Based on the Psychiatric Inpatient Medical Claim of the National Health Insurance Research Database of Taiwan, a total of 185,689 insured psychiatric patients during 2000 to 2005 were identified. After excluding patients with prior history of schizophrenia, only 42,273 newly diagnosed patients were included. Among them, 1,631 patients ever receiving thioridazine for more than 30 days within 6 months were selected and paired with 6,256 randomly selected non-thioridazine controls. These patients were traced till 2012/12/31 to see if they have any malignancy. Results The incidence rates of hypertension and cerebrovascular disease were higher among cases than among matched controls. The incidence of hyperlipidemia, coronary artery disease and chronic pulmonary disease did not differ between the two groups. By using Cox proportional hazard model for cancer incidence, the crude hazard ratio was significantly higher in age, hypertension, hyperlipidemia, cerebrovascular disease, coronary artery disease and chronic pulmornary disease. However, after adjusting for other covariates, only age and hypertension remained significant. Thioridazine use in adult patients with schizophrenia had no significant association with cancer. Conclusion Despite our finding that thioridazine use had no prevention in cancer in adult patients with schizophrenia. Based on the biological activity, thioridazine is a potential anticancer drug and further investigation in human with cancer is warranted.
Mei-Chen Lee,Shu-Fang Vivienne Wu,Nan-Chen Hsieh,Juin-Ming Tsai 한국간호과학회 2016 Asian Nursing Research Vol.10 No.4
Purpose: Chronic kidney disease (CKD) is a condition characterized by the gradual loss of kidney function over time. Self-management programs have been widely applied to chronic disease education programs, which are designed to delay deteriorating kidney functions, preclude depression, and improve quality of life. This study aims to analyze effectiveness of self-management programs in bettering CKD patients' eGFR, mitigating depression symptoms and improving quality of life in randomized control or clinical trials. Methods: Using key terms, a search was conducted in English-language, peer-reviewed journals on CKD that were published between 2002 and 2014 on databases including CINAHL, Cochrane Library, MEDLINE. The measurable variables included CKD patients' eGFR, depression, and quality of life. Random and fixed effects meta analysis were applied with standard error and correlation based measure of effect size. Results: Eight studies met the inclusion criteria. A self-management program significantly impacted CKD patients' depression and mental quality-of-life dimensions, with an effect size of .29 [95% confidence interval (CI) (0.07, 0.53)] and .42 [95% CI ( 0.75, 0.10)]. However, the intervention of a selfmanagement program had no significant effect on patients' eGFR as well as physical quality-of-life dimensions, with effect sizes of .06 [95% CI ( 0.69, 0.81)] and .16 [95% CI ( 0.81, 0.50)]. Conclusions: Self-management programs of patients with chronic kidney disease can improve the depression and mental quality of life. Aside from providing more objective evidence-based results, this study provides a reference for clinical health care personnel who tend to patients with CKD.
Valuation of Guaranteed Contracts Set Relative to Cross-currency Stochastic Rates of Return
Tsung-Yu Hsieh,Chi-Hsun Chou,Son-Nan Chen 한국증권학회 2014 Asia-Pacific Journal of Financial Studies Vol.43 No.4
We derive the pricing formulas for guaranteed contracts with guaranteed minimum rates ofreturn linked to cross-currency stochastic rates of return under a cross-currency framework. These rates are often embedded in contracts such as life and pension insurance policies, guaranteedinvestment contracts, and index-linked bonds. Valuation of such contracts has notbeen investigated in the previous literature. Our research finds that the past valuation ofthese rates via a single-currency framework causes significant underestimation under bothmaturity and (especially) multi-period guarantees. Our pricing formulas are more suitable,tractable, and feasible in practice than those in the previous literature.